Test group:intraperitoneal perfusion BIOTTT001

2 trials

Sponsors

The First Affiliated Hospital of China Medical University

Conditions

Peritoneal metastatic carcinomaperitoneal metastatic carcinoma

Phase 1

Phase I clinical study on the safety, tolerability, pharmacokinetics and efficacy of intraperitoneal perfusion recombinant human nsIL12 oncolytic adenovirus (BIOTTT001) in patients with peritoneal metastatic cancer

RecruitingChiCTR2300069323

The First Affiliated Hospital of China Medical Universityperitoneal metastatic carcinoma

Start: 2022-11-10Updated: 2023-05-29

Phase 2

Phase II clinical study on the safety, tolerability, pharmacokinetics and efficacy of intraperitoneal perfusion recombinant human nsIL12 oncolytic adenovirus (BIOTTT001) in patients with peritoneal metastatic cancer

Active, not recruitingChiCTR2300069322

The First Affiliated Hospital of China Medical UniversityPeritoneal metastatic carcinoma

Start: 2023-05-01Updated: 2023-05-29

Related Papers

Phase I study of oncolytic adenovirus BioTTT001 in patients with peritoneal carcinomatosis.

Journal of Clinical Oncology2025-05-28